Converge Bio has raised $5.5 million in seed funding led by TLV Partners.WHAT IT DOES
Converge Bio is a generative AI hub for Biotech and Pharma that allows the accelerated discovery and development of drugs…
What You Should Know:
– Converge Bio, a generative AI platform for accelerated drug discovery and development, today announced it has raised $5.5 million in seed funding, led by TLV Partners.
– Converge Bio’s platform uses large language…
Continue Reading
Former President Donald Trump’s return to the White House is certain to bring about changes across many facets of the healthcare sector — including reproductive care, federal insurance programs and prescription drugs.
Experts interviewed for…
Continue Reading
Global clinical-stage biotech company HuidaGene Therapeutics has received FDA clearance to move forward with its application for its investigational drug, a CRISPR/Cas13 RNA-editing therapy to treat neovascular age-related macular degeneration (nAMD) dubbed HG202, developed…
Continue Reading
In a series of articles to promote INVEST 2025 in Chicago April 29-30, we are highlighting investment insights and perspectives. At the centerpiece of this boutique event for traditional and strategic healthcare investors, startups…
Continue Reading
The past few years have seen a surge in demand for healthcare AI. This doesn’t show any signs of stopping soon — with three-quarters of the country’s providers and payers reporting that they have…
Continue Reading
Sam Anwar, Chief Technology Officer, eClinical Solutions
McKinsey & Company estimates it takes up to 12 years to introduce a new drug to the market – a lengthy timeline comprised of many factors including technology…
Continue Reading
AI biotech company Owkin announced a partnership with pharma giant AstraZeneca to develop an AI-powered tool designed to pre-screen for gBRCA mutations (gBRCAm) in breast cancer directly from digitized pathology slides.According to Owkin, BRCA…
Continue Reading
Funding will Support Expanded Commercialization Efforts for PreciseBreast Risk Assessment
PreciseDx, a leading innovator in oncology diagnostics leveraging Artificial Intelligence (AI) for new, morphology-driven disease analysis, today announced that it has raised $20.7 million in…
There is still a lot we don’t know when it comes to GLP-1s. How do these drugs’ side effects vary across different patients? How effective are these medications in the long term? Are barriers…
Continue Reading
